Mi-Hua Tao

CURRENT POSITIONS

Research Fellow and Professor

EDUCATIONAL AND CAREER EXPERIENCES

1985-1990	Ph.D. (Microbiology/Immunology), Columbia University, New York.
1990-1993	Postdoctoral fellow (Oncology) Stanford University, Palo Alto.
1993-2004	Assistant Research Fellow/Associate Research Fellow, IBMS, Academia Sinica
1997-1999	Coordinator, Division of Cancer Research, IBMS, Academia Sinica
2003-2004	Chief Manager, Animal Center, IBMS, Academia Sinica
2005-2006	Coordinator, Division of Infectious Disease and Immunology, IBMS, Academia Sinica
2006-2008	Deputy Director, IBMS, Academia Sinica
2004/-	Research Fellow, IBMS, Academia Sinica

PUBLICATION/ AWARDS AND HONORS/ OWNED PATENTS

1. Pan, W. Y., C. H. Lo, C. C. Chen, P. Y. Wu, S. R. Roffler, S. K. Shyue, & M. H. Tao*. (2012) *Cancer immunotherapy using a membrane-bound interleukin 12 with B7-1 transmembrane and cytoplasmic domains*. **Mol. Ther.** 20:927-37
2. Hsu, Y. C., H. P. Huang, I. S. Yu, K. Y. Su, S. R. Lin, W. C. Lin, H. L. Wu, G. Y. Shi, M. H. Tao, C. H. Kao, Y. M. Wu, P. E. Martin, S. Y. Lin, P. C. Yang, & S. W. Lin. (2012) *Serine protease hepsin regulates hepatocyte size and hemodynamic retention of tumor cells via hepatocyte growth factor signaling*. **Hepatology** 56:1913-23.
3. Sun, C. P., T. H. Wu, C. C. Chen, P. Y. Wu, Y. M. Shih, K. Tsuneyama & M. H. Tao*. (2013) *Studies of Efficacy and Liver Toxicity Associated With AAV-mediated RNA Interference*. **Human Gene Ther** 24:739-50.
4. Shih, Y. M., C. P. Sun, H. H. Chou, T. H. Wu, C. C. Chen, P. Y. Wu, Y. C. Chen, K. D. Bissig & M. H. Tao*. (2015) *Combinatorial RNA interference therapy prevents selection of pre-existing HBV variants in human liver chimeric mice*. **Sci Rep** 5:15259
5. Zhang, T. Y., Q. Yuan, J. H. Zhao, Y. L. Zhang, L. Z. Yuan, Y. Lan, Y. C. Lo, C. P. Sun, C. R. Wu, J. F. Zhang, Y. Zhang, J. L. Cal, X. R. Guo, X. Liu, X. B. Mo, W. X. Luo, T. Cheng, Y. X. Chen, M. H. Tao, J. W. Shih, Q. J. Zhao, J. Zhang, P. J. Chen, Y. A. Yuan & N. S. Xia. (2016) *Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen*. **Gut** 65: 658-71